Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...

Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - ...

(RTTNews) - Radius Health Inc. (RDUS) announced positive results from the ATOM Phase 3 Study evaluating TYMLOS or abaloparatide 80mcg subcutaneous (SC) for use in males with osteoporosis. The company ...

Osteoporosis-related fractures are an important health concern because of related morbidity, mortality, and cost. 2 Bruce Mitlak, M.D., the Chief Medical Officer of Radius, emphasized that "30% of all ...

Tymlos can cause mild to serious side effects. Examples include dizziness, injection site reaction, and nausea. In most cases, side effects caused by Tymlos are temporary. For most people, mild side ...

"The real-world data presented further supports the favorable efficacy and safety profile of TYMLOS and why it is an important treatment option in the management of osteoporosis," said Dr. Felicia ...

“Our focus on postmenopausal osteoporotic-related fracture patients continues to gain traction,” commented Sal Grausso, Chief Commercial Officer for the Company. Grausso added that “We are making ...

The US Food and Drug Administration (FDA) has approved an additional indication for abaloparatide (Tymlos) to increase bone density in men with osteoporosis at high risk for fracture, or in male ...